All In MedTech

Device Trial Radar · NCT01518322

Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

An Observational, Multi-Center, Single-Visit Study to Assess the Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

Last checked: Nov 19, 2026Latest source record: Aug 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

235

Actual

Start

Nov 2011

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
Aerocrine ABNot on our public-company list
Sponsor type
Industry
First posted
Jan 26, 2012

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 7 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Overall Aim: To better understand the diagnostic process for prolonged respiratory events and determine the potential role of FeNO in assessing the possibility of asthma as the symptoms etiology. Study Objectives: The specific objectives of this study are to: * Determine the frequency of ICS prescription for the treatment of non-specific lower respiratory symptoms. * Determine the frequency of asthma diagnosis as an etiology for the non-specific lower respiratory symptoms. * Explore the value of FeNO in identifying asthma as the etiology of the non-specific lower respiratory symptoms. Number of Subjects: It is anticipated that up to approximately 3,000 patients will be asked to complete the brief screening questionnaire that will be used to identify up to approximately 280 eligible patients who meet the study inclusion/exclusion criteria during a (approximately) 4 to 6 week study enrollment period. Reference Product: NIOX MINO® Duration of the participants involvement in the investigation: Single Visit Performance assessments: Fractional Exhaled Nitric Oxide (FeNO) Measurements will be performed using the NIOX MINO® device according to "Instructions for NO measurements" which will be provided to each Investigative site prior to patient enrollment. Safety Assessments: The Investigator is responsible for the detection, reporting, and documentation of events meeting the definition of an Adverse Event (AE) and/or Serious Injuries as provided in this clinical investigation plan from the time of informed consent/assent and during the study period. Criteria for Evaluation: The relationship(s) between FeNO and both the diagnosis of asthma and prescription of ICS will be explored by correlation, measures of concordance and logistic modeling.

Conditions

  • Asthma

Interventions

  • NIOX MINO®Device

    Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relationship Between FeNO and the Diagnosis of AsthmaTime frame: Single-visit, one (1) FeNO measurement. One (1) timepoint (Day 1)
  2. Relationship Between FeNO and the Prescription of ICS in Primary Care PracticesTime frame: Single-visit, one (1) FeNO measurement. One (1) timepoint (Day 1)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Olmstead Medical Center Byron

    Byron, Minnesota

  • Olmstead Medical Center Chatfield

    Chatfield, Minnesota

  • Olmstead Medical Center Pine Island

    Pine Island, Minnesota

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.